Hereditary Angioedema

CTAF

ICER will assess the comparative clinical effectiveness and value of therapies for hereditary angioedema, a rare condition characterized by attacks of deep tissue swelling within the skin and/or mucosa. The report is expected to focus on four therapies for the prevention of hereditary angioedema attacks: lanadelumab (Shire), which is currently under review by the FDA with an approval decision expected in August of 2018, and three C1 esterase inhibitors (Haegarda®, CSL Behring; Cinryze®, Shire; and Ruconest®, Pharming*). This list is tentative and subject to change.

*Ruconest (Pharming) was removed from the ICER review in September 2018 because the treatment is no longer under consideration for FDA approval for long-term prophylaxis.

Associated Meetings

October 25, 2018 10am-4pm PT

California Endowment Oakland Conference Center
2000 Franklin St.
Oakland, CA 94612

CTAF will convene to review ICER's assessment of therapies for hereditary angioedema.


Key Dates

Associated Materials

03/23/2018 – 04/09/2018

04/12/2018

Open to public comment until May 2, 2018. For more information about submitting a public comment, including formatting specifications, please see our engagement page.